E-Updates - February 2018



2018 Genitourinary cancers symposium february 8-10

The 2018 Genitourinary Cancers Symposium: Translating Evidence to Multidisciplinary Care gave physicians and other members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies the opportunity to receive critical updates and recommendations to improve the care of patients with these cancers. The symposium explored the latest science and its clinical application, and featured keynote lectures from world-renowned experts on the most clinically relevant research across the spectrum of GU cancers, along with abstracts with novel and emerging data. Co-sponsors of the symposium included the American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology.

The Alliance for Clinical Trials in Oncology presented the following abstract during the annual symposium in San Francisco, CA.

Alliance A031203
Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial
Lead author: Daniel J. George, MD
Sessions: Rapid-Fire Abstract Session | Poster Session C: Renal Cell Cancer | Saturday, February 10
Abstract #: 582 | Citation: J Clin Oncol 36, 2018 (suppl 6S; abstr 582)
Learn more about the trial.